MeiraGTx Holdings PLC intends to file for an IPO of up to $86.3 million.
The company's ordinary shares will trade on the Nasdaq Global Market under the ticker MGTX.
MeiraGTx said it will use proceeds to develop its most advanced product candidates, scale-up manufacturing facilities and fund research and development of other products.
The New York-based clinical-stage gene therapy company has four ongoing clinical programs. The company's pipeline focuses on inherited retinal diseases, severe forms of xerostomia, or dry mouth syndrome, and conditions that affect the neurons in the brain.
Chardan is acting as lead manager in the offering. Barclays, BofA Merrill Lynch and Evercore ISI serve as joint book-running managers.